A randomized trial comparing ReCell® system of epidermal cells delivery versus classic skin grafts for the treatment of deep partial thickness burns

Gravante, Gianpiero; Fede, M; Araco, Antonino; Grimaldi, Michele; Angelis, Bárbara De; Arpino, A.; Cervelli, Valerio; Montone, Antonio

doi:10.1016/j.burns.2007.04.011

Cited by 186 publications

(111 citation statements)

References 20 publications

Supporting

Mentioning

105

Contrasting

Unclassified

Order By: Relevance

“…Da bei großflächigen Verbrennungen die Deckung mittels Autografts nicht immer möglich ist, wurden alternative Epidermis-und Dermisersatzmaterialien erforscht [12]. Die Forschung auf dem Gebiet der Schaffung von Gewebe zum Einsatz bei rekonstruktiven Eingriffen wird als Tissue Engineering bezeichnet [13,14].…”

Section: Diskussionunclassified

Chirurgische Behandlung von Verbrennungen

et al. 2017

View full text Add to dashboard Cite

show abstract

Section: Diskussionunclassified

Chirurgische Behandlung von Verbrennungen

et al. 2017

View full text Add to dashboard Cite

show abstract

“…For skin, several autologous and allogeneic dermal and bi‐layered (epidermis and dermis) constructs have been described over the past years to heal venous and arterial leg ulcers, diabetic foot ulcers and pressure ulcers (Falanga & Sabolinski, 1999; Jones, Nelson, & Al‐Hity, 2013; Kirsner et al, 2012; Marston, Hanft, Norwood, & Pollak, 2003; Veves, Falanga, Armstrong, & Sabolinski, 2001; Wu, Marston, & Armstrong, 2010; Zaulyanov & Kirsner, 2007). Also, application of autologous epidermal cells has been described for treating large burn wounds (Gardien et al, 2016; Gravante et al, 2007; Wood et al, 2012). Difficult‐to‐heal wounds in the oral mucosa arise from tumour excision, cleft palate repair and large trauma.…”

Section: Introductionmentioning

confidence: 99%

Comparison of advanced therapy medicinal product gingiva and skin substitutes and their in vitro wound healing potentials

Boink

Roffel

Breetveld

et al. 2017

J Tissue Eng Regen Med

View full text Add to dashboard Cite

Skin and oral mucosa substitutes are a therapeutic option for closing hard‐to‐heal skin and oral wounds. Our aim was to develop bi‐layered skin and gingiva substitutes, from 3 mm diameter biopsies, cultured under identical conditions, which are compliant with current European regulations for advanced therapy medicinal products. We present in vitro mode of action methods to (i) determine viability: epithelial expansion, proliferation (Ki‐67), metabolic activity (MTT assay); (ii) characterize skin and gingiva substitutes: histology and immunohistochemistry; and (iii) determine potency: soluble wound healing mediator release (enzyme‐linked immunosorbent assay). Both skin and gingiva substitutes consist of metabolically active autologous reconstructed differentiated epithelium expanding from the original biopsy sheet on a fibroblast populated connective tissue matrix (donor dermis). Gingival epithelium expanded 1.7‐fold more than skin epithelium during the 3 week culture period. The percentage of proliferating Ki‐67‐positive cells located in the basal layer of the gingiva substitute was >1.5‐fold higher than in the skin substitute. Keratins 16 and 17, which are upregulated during normal wound healing, were expressed in both the skin and gingiva substitutes. Notably, the gingiva substitute secreted higher amounts of key cytokines involved in mitogenesis, motogenesis and chemotaxis (interleukin‐6 > 23‐fold, CXCL8 > 2.5‐fold) as well as higher amounts of the anti‐fibrotic growth factor, hepatocyte growth factor (>7‐fold), compared with the skin substitute. In conclusion, while addressing the viability, characterization and potency of the tissue substitutes, important intrinsic differences between skin and gingiva were discovered that may explain in part the superior quality of wound healing observed in the oral mucosa compared with skin.

show abstract

“…Newer devices, including cell spray formulations (following digestion of small pieces of skin with trypsin) that can contain keratinocytes, melanocytes, Langerhans cells, and fibroblasts have also been developed (Gravante et al 2007) and used in clinical trials to augment wound healing (Kirsner et al 2012). In addition, the use of noncutaneous cells, such as bone marrow (BM) cells, has been explored in skin regeneration, particularly with a view of treating the entire skin (and possibly mucous membranes) rather than limited areas of damaged skin (Wagner et al 2010).…”

Section: Keratinocyte Culture and Skin Graftingmentioning

confidence: 99%

Cell Therapy in Dermatology

Petrof

Abdul‐Wahab

McGrath

2014

Cold Spring Harbor Perspectives in Medicine

View full text Add to dashboard Cite

Harnessing the regenerative capacity of keratinocytes and fibroblasts from human skin has created new opportunities to develop cell-based therapies for patients. Cultured cells and bioengineered skin products are being used to treat patients with inherited and acquired skin disorders associated with defective skin, and further clinical trials of new products are in progress. The capacity of extracutaneous sources of cells such as bone marrow is also being investigated for its plasticity in regenerating skin, and new strategies, such as the derivation of inducible pluripotent stem cells, also hold great promise for future cell therapies in dermatology. This article reviews some of the preclinical and clinical studies and future directions relating to cell therapy in dermatology, particularly for inherited skin diseases associated with fragile skin and poor wound healing.

show abstract

A randomized trial comparing ReCell® system of epidermal cells delivery versus classic skin grafts for the treatment of deep partial thickness burns

Cited by 186 publications

References 20 publications

Chirurgische Behandlung von Verbrennungen

Chirurgische Behandlung von Verbrennungen

Comparison of advanced therapy medicinal product gingiva and skin substitutes and their in vitro wound healing potentials

Cell Therapy in Dermatology

Contact Info

Product

Resources

About